Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi, Francisco Sánchez-Vega, Konnor La et al. · Journal of Clinical Oncology · 2018 · 1.4K citations · Full text

Medicine, Immunology, Oncology +17

A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate

Michael E. Pacold, Kyle R. Brimacombe, Sze Ham Chan et al. · Nature Chemical Biology · 2016 · 589 citations · Full text

Pharmacy, Biochemistry, Medicinal Chemistry +14

<i>TP53, STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

Jérôme Biton, Audrey Mansuet‐Lupo, Nicolas Pécuchet et al. · Clinical Cancer Research · 2018 · 361 citations

Life Sciences, Immunology, Oncology +17

Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Clinical Cancer Research · 2016 · 297 citations · Full text

Medicine, Oncology, Pharmacology +16

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Catherine Labbé, Michael Cabanero, Grzegorz Korpanty et al. · Lung Cancer · 2017 · 246 citations

Medicine, Molecular Genetics, Oncology +15